Sorry, you need to enable JavaScript to visit this website.

A Trial to Measure the Safety and Efficacy of Vyndaqel Treatment in Patients With Transthyretin Amyloid Cardiomyopathy

Open-Label Safety and Efficacy Evaluation of FX-1006A in Patients With V122I or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy

Category & Conditions: Cardiovasular Diseases and Conditions
Medicine: VYNDAQEL® (TAFAMIDIS MEGLUMINE) CAPSULES AND VYNDAMAX™ (TAFAMIDIS) CAPSULES
ClinicalTrials.gov Identifier (NCT): NCT00935012
Protocol ID: B3461026
    Share
PrintDownload
Open Plain Language Summary Result: Click here